Patents Assigned to Icos Corporation
  • Methods of identifying agents that modulate the binding between MDC and an MDC receptor
    Patent number: 6498015
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: December 24, 2002
    Assignee: ICOS Corporation
    Inventors: Ronald Godiska, Patrick W. Gray, Carol J. Raport
  • Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
    Patent number: 6486186
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: November 26, 2002
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20020169196
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: February 15, 2002
    Publication date: November 14, 2002
    Applicant: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Laurence E. Burgess, Stephen T. Schlachter
  • Lectomedin materials and methods
    Patent number: 6479256
    Abstract: Disclosed are novel seven transmembrane receptor polypeptides having characteristic extracellular structure including lectin-binding, olfactomedin-like and mucin-like domains.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: November 12, 2002
    Assignee: ICOS Corporation
    Inventor: Joel S. Hayflick
  • Carboline derivatives as cGMP phosphodiesterase inhibitors
    Patent number: 6462047
    Abstract: Compounds of general structural formula (I) wherein A represents a 5- or 6-membered heteroaryl group containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and use of the compounds, and salts and solvates thereof, as therapeutic agents, are disclosed.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: October 8, 2002
    Assignee: ICOS Corporation
    Inventors: Agnes Bombrun, Françoise Gellibert
  • Materials and methods for modulating differentiation
    Publication number: 20020142976
    Abstract: This invention generally relates to materials and methods for modulating the differentiation of cells. Specifically provided are methods to promote or inhibit cell differentiation and methods to identify compounds that promote cellular differentiation.
    Type: Application
    Filed: March 27, 2001
    Publication date: October 3, 2002
    Applicant: ICOS Corporation
    Inventors: Merl F. Hoekstra, Mathew J. Thayer
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6458787
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: October 1, 2002
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlacter
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6455562
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: September 24, 2002
    Assignee: Icos Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6444671
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: September 3, 2002
    Assignee: ICOS Corporation
    Inventor: John J. Gaudino
  • Tetracyclic derivatives, process of preparation and use
    Publication number: 20020119976
    Abstract: A compound of formula (I) 1
    Type: Application
    Filed: February 5, 2002
    Publication date: August 29, 2002
    Applicant: ICOS Corporation
    Inventor: Alain Claude-Marie Daugan
  • Methods of inhibiting locomotor damage following spinal cord injury with &agr; D-specific antibodies
    Patent number: 6432404
    Abstract: Methods to treat spinal cord injury using &agr;d monoclonal antibodies are disclosed.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: August 13, 2002
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Monica Van der Vieren
  • Monocyte chemotactic protein-5 materials and methods
    Publication number: 20020102642
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C—C chemokine designated MCP-5. Also provided are purified and isolated chemokine protein, fragments and polypeptide analogs thereof, antibodies thereto, and materials and methods for the recombinant production thereof. These products are useful in therapeutic, diagnostic and medical imaging applications.
    Type: Application
    Filed: June 1, 2001
    Publication date: August 1, 2002
    Applicant: ICOS Corporation
    Inventors: Ronald Godiska, Patrick W. Gray
  • Therapeutic uses of PAF-AH products in diabetes
    Publication number: 20020102231
    Abstract: The present invention relates to uses of PAF—AH products to prevent or slow the progression of diabetes, particularly insulin dependent diabetes mellitus.
    Type: Application
    Filed: January 31, 2001
    Publication date: August 1, 2002
    Applicant: ICOS Corporation
    Inventors: Gregory N. Dietsch, Gary M. Peterman, Albert S. Yu
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6423710
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: July 23, 2002
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
  • Chitinase chitin-binding fragments
    Patent number: 6399571
    Abstract: The present invention provides chitin-binding fragments of human chitinase, fragment analogs, purified and isolated polynucleotide sequences encoding such fragments and analogs, and materials and methods for the recombinant production of human chitinase fragment products which are expected to be useful as in products for detecting chitin, binding chitin, and treating fungal infections or for development of products useful for treating the same.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: June 4, 2002
    Assignee: ICOS Corporation
    Inventors: Patrick W. Gray, Larry W. Tjoelker
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20020065302
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: December 14, 2001
    Publication date: May 30, 2002
    Applicant: ICOS Corporation
    Inventors: Kerry W. Fowler, Amy Oliver, Joshua Odingo
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6376489
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory disease and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: April 23, 2002
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Laurence E. Burgess, Stephen T. Schlachter
  • Chitinase materials and methods
    Patent number: 6372212
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding human chitinase. Also provided are materials and methods for the recombinant production of human chitinase products which are expected to be useful as products for treating fungal infections or for development of products useful for treating the same.
    Type: Grant
    Filed: June 16, 1997
    Date of Patent: April 16, 2002
    Assignee: ICOS Corporation
    Inventor: Patrick W. Gray
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6372777
    Abstract: Pyrrole compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: April 16, 2002
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Amy Oliver, Carmen C. Hertel
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20020042435
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: September 18, 2001
    Publication date: April 11, 2002
    Applicant: ICOS Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo